Pilocarpine-Induced Effects on Salivary Secretion as a Pharmacological Biomarker for Cholinergic Parasympathetic Activation.

Autor: Treijtel N; Department of Clinical Pharmacology and Experimental Development, Astellas Pharma Europe B.V. Leiden, The Netherlands., Groenendaal-van de Meent D; Department of Clinical Pharmacology and Experimental Development, Astellas Pharma Europe B.V. Leiden, The Netherlands., Michon I; Department of Clinical Pharmacology and Experimental Development, Astellas Pharma Europe B.V. Leiden, The Netherlands., Korstanje C; Drug Discovery Research, Astellas Pharma Europe B.V. Leiden, The Netherlands., Meijer J; Drug Discovery Research, Astellas Pharma Europe B.V. Leiden, The Netherlands., Francke K; PAREXEL International Berlin, Berlin, Germany., Grossmann M; PAREXEL International Berlin, Berlin, Germany., de Vries M; Department of Clinical Pharmacology and Experimental Development, Astellas Pharma Europe B.V. Leiden, The Netherlands.

Publikováno v: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Jan; Vol. 11 (1), pp. 25-33. Date of Electronic Publication: 2021 Nov 26.

Are there different patterns of detrusor overactivity which are clinically relevant? ICI-RS 2018.

Autor: Gajewski JB; Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada., Gammie A; Bristol Urological Institute, Southmead Hospital, Bristol, UK., Speich J; Department of Mechanical and Nuclear Engineering, College of Engineering, Virginia Commonwealth University, Richmond, Virginia., Kirschner-Hermanns R; Department of Neuro-Urology, University Hospital of the Rheinische Friedrich-Wilhelms University Bonn, Bonn, Germany.; Department of Urology and Paediatric Urology, Neuro-Urology, Neurological Rehabilitation Center 'Godeshoehe e.V.', Bonn, Germany., De Wachter S; Department of Urology, University of Antwerp, Antwerp, Belgium., Schurch B; Neurourology Unit Department of Neurosciences, University Hospital Lausanne, Lausanne, Switzerland., Korstanje C; Department of Drug Discovery Science & Management, Astellas Pharma Europe BV, Leiden, The Netherlands., Valentini F; Université Pierre et Marie Curie, Hôpital Rothschild, Paris, France., Rahnama'i MS; Uniklinik Aachen RWTH, Aachen, Germany.; Maastricht University, The Netherlands.

Publikováno v: Neurourology and urodynamics [Neurourol Urodyn] 2019 Dec; Vol. 38 Suppl 5, pp. S40-S45.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Autor: Andersson KE; Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA Aarhus Institute for Advanced Sciences (AIAS), Aarhus University, Aarhus, Denmark., Choudhury N; Astellas Pharma Europe Ltd., 2000 Hillswood Drive, Chertsey, Surrey, KT16 0RS, UK., Cornu JN; Department of Urology, Rouen University Hospital and University of Rouen, Rouen, France., Huang M; Astellas Pharma Europe Ltd., Chertsey, Surrey, UK., Korstanje C; Astellas Pharma Europe Research and Development, Leiden, The Netherlands., Siddiqui E; Astellas Pharma Medical and Development, Leiden, The Netherlands., Van Kerrebroeck P; Maastricht University Medical Centre, Maastricht, The Netherlands.

Publikováno v: Therapeutic advances in urology [Ther Adv Urol] 2018 Jul 06; Vol. 10 (8), pp. 243-256. Date of Electronic Publication: 2018 Jul 06 (Print Publication: 2018).

Comparison of the efficacy and complications of tolterodine and α-adrenergic receptor blockers in improving ureteral stent-related symptoms: A systematic review and meta-analysis.

Autor: Liu, Ming^1,2 (AUTHOR), Liu, Shangjing² (AUTHOR), Mao, Qiancheng² (AUTHOR), Zou, Qingsong² (AUTHOR), Cui, Yuanshan² (AUTHOR) doctorcuiys@163.com, Wu, Jitao² (AUTHOR) doctorcuiys@163.com

Publikováno v: PLoS ONE. 5/3/2024, Vol. 19 Issue 5, p1-14. 14p.